Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn's & Colitis Congress
ALPN-101 efficacious in a preclinical model of inflammatory bowel disease

January 24, 2020

SEATTLE, WA, January 24, 2020 – Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead program, ALPN-101, at the 2020 Crohn's & Colitis Congress in Austin, Texas.

In the poster titled, "ALPN-101, A First-In-Class Dual ICOS/CD28 Antagonist, Demonstrates Efficacy in Patient-Derived PBMC *In Vitro* and in an *In Vivo* T Cell Transfer Model of Chronic Inflammatory Bowel Disease (IBD)," ALPN-101 modulated inflammatory cytokines *in vitro* from human IBD peripheral blood mononuclear cells (PBMC) more potently than CD28 or ICOS single-pathway inhibitors. In addition, it significantly reduced disease activity in the CD4+CD45RBhi T cell transfer mouse colitis model.

"This new data further adds to the future development options for ALPN-101, which has already demonstrated differentiated activity in some preclinical models of graft-versus-host disease and rheumatic diseases," commented Stanford Peng, MD PhD, President and Head of Research and Development at Alpine. "Now that our first-in-human study in healthy volunteers has been completed, we look forward to clinical trials in such diseases."

The full poster presentation can be found at alpineimmunesciences.com, at this (LINK).

About ALPN-101
ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™), a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases. In preclinical models of graft versus host disease, inflammatory arthritis, connective tissue disease, and multiple sclerosis, ALPN-101 demonstrates efficacy superior to agents blocking the CD28 – CD80/86 and/or ICOS - ICOSL pathways alone.

About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients' lives via unique protein engineering technologies. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28. ALPN-101 has recently completed enrollment in a Phase 1 healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

Investor Relations:
Pure Communications
Courtney Dugan, 212-257-6723
cdugan@purecommunications.com

Media Relations:
Pure Communications
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com